Benitec Biopharma Appoints New CMO, Adds Directors

Ticker: BNTC · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1808898

Benitec Biopharma INC. 8-K Filing Summary
FieldDetail
CompanyBenitec Biopharma INC. (BNTC)
Form Type8-K
Filed DateMar 8, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001 B, $5.21
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-of-directors, executive-appointment

TL;DR

Benitec Biopharma shakes up leadership: new CMO, two new directors, one CMO departs.

AI Summary

Benitec Biopharma Inc. announced on March 6, 2024, the appointment of Dr. Joseph S. Carillo as Chief Medical Officer and the election of Ms. Jennifer L. D. Allison and Mr. David S. Wood to its Board of Directors. The company also reported the departure of Dr. B.K. Singh from his role as Chief Medical Officer. These changes are effective immediately.

Why It Matters

These executive and board changes could signal a shift in the company's strategic direction or operational focus in the biopharmaceutical sector.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer?

Dr. Joseph S. Carillo has been appointed as the new Chief Medical Officer.

Who were elected to the Board of Directors?

Ms. Jennifer L. D. Allison and Mr. David S. Wood were elected to the Board of Directors.

Who has departed from their role as Chief Medical Officer?

Dr. B.K. Singh has departed from his role as Chief Medical Officer.

What is the effective date of these changes?

The changes are effective as of March 6, 2024.

What is the principal executive office address of Benitec Biopharma Inc.?

The principal executive office address is 3940 Trust Way, Hayward, California 94545.

Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2024-03-08 16:17:00

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: March 8, 2024 By: /s/ Dr. Jerel A. Banks Name: Dr. Jerel A. Banks Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing